Pacira BioSciences, Inc. PCRX
At closeNov 6, 2026, 4:38 PM EST
After hours · Nov 6, 4:38 PM ET
- YTD
- +40.77%
- 1 year
- +72.65%
- Market cap
- 1.45B
- Revenue (ttm)
- 743.30M
- Profit margin
- 5.08%
- EPS (ttm)
- 0.35
- Shares out
- 39.91M
- P/E ratio
- 104.09
- Forward P/E
- 10.53
- YTD return
- +40.77%
- 1-year return
- +72.65%
- Volume
- 537.09K
- Avg volume
- 1.25M
- Open
- 36.42
- Previous close
- 36.42
- Day's range
- 36.42 – 36.45
- 52-week range
- 19.16 – 36.43
- Price target
- 33.57 (-7.8%)
- Earnings date
- Mar 4, 2027
15m +0.03 (+0.08%)
Key statistics
- Enterprise value
- 1.50B
- PEG ratio
- 0.99
- Price / sales
- 1.96
- Price / book
- 2.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -1.60%
- Free cash flow
- 198.57M
- Total cash
- 295.58M
- Total debt
- 340.28M
- Return on equity
- 5.24%
- Short % of float
- 15.33%
- 50-day average
- 29.96
- 200-day average
- 25.17
Analyst view
- Target (low)
- 25.00
- Target (mean)
- 33.57
- Target (high)
- 36.50
- Strong buy0
- Buy0
- Hold9
- Sell0
- Strong sell0
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate 0.83442.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | 0.834 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.732 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 0.646 | 0.73 | +0.08 | +13.00% |
| Apr 30, 2026 | Mar 31, 2026 | 0.61 | 0.60 | -0.01 | -1.64% |
| Feb 26, 2026 | Dec 31, 2025 | 0.85 | 0.57 | -0.28 | -32.94% |
| Nov 6, 2025 | Sep 30, 2025 | 0.65 | 0.70 | +0.05 | +7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | Truist Securities | down | Buy | Hold |
| Oct 9, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 9, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 8, 2026 | JP Morgan | up | Underweight | Neutral |
| Oct 8, 2026 | Jefferies | down | Buy | Hold |
| Oct 8, 2026 | Needham | down | Buy | Hold |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- pacira.com
News
Pacira BioSciences Withdraws 2026 Guidance Pending Proposed Merger With Viatris 
Viatris Reports Third-Quarter 2026 Financial Results 
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU? 
Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders? 
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU? 
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders 
Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr 
Top 3 Health Care Stocks That May Fall Off A Cliff In October 
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5 
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5
Your note
Sign in to keep a note on PCRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BREGE LAURA A | Director | Stock Award(Grant) | Jun 9, 2026 | 30,120 |
| CROSS SHAWN M. | Chief Financial Officer | Sale | Apr 22, 2026 | 105,341 |
| FROIMSON MARK | Director | Stock Award(Grant) | Jun 9, 2026 | 26,541 |
| GAUGLER DARYL | Chief Operating Officer | Stock Award(Grant) | Dec 30, 2024 | 115,443 |
| KRONENFELD MARK A | Director | Stock Award(Grant) | Jun 10, 2025 | 34,901 |
| LEE FRANK DON | Chief Executive Officer | Stock Award(Grant) | Feb 10, 2026 | 660,831 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.82% | 6,705,809 | 244.29M | Jun 29, 2026 |
| Doma Perpetual Capital Management LLC | 6.97% | 2,777,794 | 101.20M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.04% | 2,406,238 | 87.66M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 5.70% | 2,271,610 | 82.75M | Sep 29, 2026 |
| State Street Corporation | 5.17% | 2,059,977 | 75.04M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 4.89% | 1,950,332 | 71.05M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 2,372,015 | 86.41M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,198,792 | 43.67M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.57% | 1,023,867 | 37.30M | Sep 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.26% | 901,996 | 32.86M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.15% | 856,213 | 31.19M | Jun 29, 2026 |
| IMPAX FUNDS SERIES TRUST I-Impax Small Cap Fund | 1.88% | 750,027 | 27.32M | Jun 29, 2026 |